logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Therapeutic Area
    3. Trauma & Toxicology

    Trauma & Toxicology drugs

    FiltersReset Filters
    4 results

    • auvi-q

      (epinephrine)
      kaleo, Inc
      Usage: AUVI-Q® is indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis due to insect stings, food, medications, and other allergens. It is intended for immediate self-administration in individuals at risk for anaphylaxis and is not a substitute for medical care.

    • panhematin

      (hemin)
      Recordati Rare Diseases, Inc.
      Usage: PANHEMATIN is indicated for alleviating recurrent acute intermittent porphyria attacks linked to the menstrual cycle in women when carbohydrate therapy is insufficient. It aims to prevent severe attacks, but is not effective for repairing existing neuronal damage. Prior carbohydrate loading is recommended before administration.

    • rayos

      (prednisone)
      Horizon Therapeutics USA, Inc.
      Usage: RAYOS is indicated for severe allergic conditions, various dermatologic and endocrine diseases, gastrointestinal disorders (like Crohn's and ulcerative colitis), hematologic issues, neoplasms, nervous system conditions (such as multiple sclerosis), certain ophthalmic diseases, organ transplant rejection, pulmonary disorders, renal conditions, rheumatologic ailments, and specific infectious diseases.

    • voraxaze

      (glucarpidase)
      BTG International Inc.
      Usage: VORAXAZE is indicated for reducing toxic plasma methotrexate levels in adults and pediatric patients with delayed clearance due to impaired renal function. It should not be used in patients with expected clearance, as it may lead to inadequate methotrexate exposure.